7 research outputs found

    Adenosine decreases the number of releasable vesicles and release probability without changing the rate of recovery from vesicle depletion.

    No full text
    <p>A, EPSC trains averaged from 10 traces evoked by 20 stimuli at 40 Hz before (<i>left</i>) and during (<i>right</i>) the application of adenosine. Stimulation artifacts were blanked for clarity. <b>B,</b> EPSC amplitudes averaged from 8 cells in response to 20 stimuli at 40 Hz before and during the application of adenosine. The amplitude of EPSC evoked by each stimulus was measured by resetting the base line each time at a point within 0.5 ms before the beginning of each stimulation artifact. <b>C,</b> Cumulative amplitude histogram of EPSCs. For each cell, the last 6 EPSC amplitudes were fit with a linear regression line and extrapolated to time 0 to estimate the readily releasable pool size (<i>Nq</i>). <b>D,</b> Adenosine decreases <i>Nq</i> (n = 8, paired t-test). <b>E,</b> Adenosine decreases release probability (<i>P<sub>r</sub></i>, n = 8, paired t-test). For each cell, <i>P<sub>r</sub></i> was calculated as the ratio of the first EPSC amplitude divided by its <i>Nq</i> obtained by linear fitting of the cumulative EPSC histogram. <b>F, </b><i>Upper:</i> experimental protocol. A conditioning train (20 stimuli at 40 Hz) was followed by a test stimulus. The intervals between the end of the conditioning train and the beginning of the test stimulus were 0.1 s, 0.5 s, 1 s, 2 s, 5 s or 10 s. The interval between each sweep containing the conditioning train and the test stimulus was 30 s to allow the refilling of the synaptic vesicles. <i>Lower:</i> EPSCs evoked by the test pulse from the same synapse at different intervals were aligned and superimposed before (<i>left</i>) and during (<i>right</i>) application of adenosine. Stimulation artifacts were blanked and labels for the traces in the presence of adenosine were omitted for clarity. <b>G,</b> Time course of recovery from depletion before and during the application of adenosine expressed as percentage recovery = (I<sub>test</sub>−I<sub>ss</sub>)/(I<sub>1st</sub>−I<sub>ss</sub>)×100, where I<sub>test</sub> is the EPSC evoked by the test pulse, I<sub>ss</sub> is the steady-state current left after the conditioning train (the average of the last 5 EPSC evoked by the conditioning train), I<sub>1st</sub> is the EPSC evoked by the 1<sup>st</sup> stimulus of the conditioning train. Data before (<i>thick line</i>) and during (<i>thin line</i>) the application of adenosine from 6 cells were fit by a single exponential function.</p

    Adenosine inhibits AMPA EPSCs by decreasing presynaptic glutamate release.

    No full text
    <p>A, Application of adenosine increased the CV of AMPA EPSCs (n = 7, p = 0.003, paired t-test). Upper panel shows 15 consecutive AMPA EPSCs recorded before and during the application of adenosine. Lower panel shows the calculated CVs from 7 cells (<i>open circles</i>) and their averages (<i>solid circles</i>). <b>B,</b> Adenosine increased PPR (n = 10, p<0.001, paired t-test). <i>Upper left</i>, AMPA EPSCs evoked by two stimulations at an interval of 50 ms before and during the application of adenosine. <i>Upper right</i>, EPSCs recorded before and during the application of adenosine were scaled to the first EPSC. Note that the second EPSC after the application of adenosine is larger than control. <i>Bottom</i>, PPRs recorded from 7 cells (<i>open circles</i>) and their averages (<i>solid circles</i>). <b>C,</b> Application of adenosine inhibited NMDA EPSCs (n = 9, p<0.001 vs. baseline, paired t-test). Upper panel shows the averaged NMDA EPSC of 5 EPSCs at different time points in the figure. <b>D,</b> Application of adenosine increased the CV of the NMDA EPSCs (n = 9, p = 0.011, paired t-test). Upper panel shows 10 successive NMDA EPSCs recorded before (<i>left</i>) and during (<i>right</i>) the application of adenosine. Lower panel shows the calculated CVs from 9 cells (<i>open circles</i>) and their averages (<i>solid circles</i>). <b>E,</b> Intracellular application of GDP-β-S via the recording pipettes did not significantly alter adenosine-induced depression of AMPA EPSCs (n = 6, p<0.001 vs. baseline, paired t-test).</p

    Adenosine-induced depression of seizure activity is mediated by activation of A<sub>1</sub> ARs and requires the functions of Gα<sub>i</sub> proteins and PKA.

    No full text
    <p><b>A,</b> Seizure events induced by bath application of picrotoxin at the saturated concentration (100 µM) in a rat slice at different times. An extracellular electrode containing ACSF was placed in layer III of the EC to record the seizure events. <b>B,</b> Time course of picrotoxin-induced seizure events (n = 7 slices). <b>C,</b> Seizure events recorded before, during and after the application of adenosine (100 µM). <b>D,</b> Summarized time course of adenosine-induced inhibition of seizure activity (n = 10 slices, p<0.001 vs. baseline, paired t-test). <b>E,</b> Concentration-response curve of adenosine-induced depression of seizure activity. Numbers in the parenthesis are the number of slices recorded from. <b>F,</b> Prior bath application of the A<sub>1</sub> AR inhibitor, DPCPX, blocked adenosine-induced depression of seizure events (n = 12 slices, p = 0.89 vs. baseline, paired t-test). <b>G,</b> Bath application of the A<sub>1</sub> AR agonist, NCPA, irreversibly suppressed the seizure events (n = 6 slices, p<0.001 vs. baseline, paired t-test). <b>H,</b> Application of antagonists to other ARs except A<sub>1</sub> ARs did not block adenosine-induced depression of epileptiform activity (One-way ANOVA followed by Dunnett test, *** p<0.001 vs. adenosine alone). <b>I,</b> Bath application of adenosine failed to depress significantly picrotoxin-induced seizure events in slices pretreated with PTX (n = 8 slices, p = 0.45 vs. baseline, paired t-test). <b>J,</b> Pretreatment of slices with and continuous bath application of the membrane permeable PKA inhibitor, KT5720, blocked adenosine-induced depression of seizure events (n = 8 slices, p = 0.7 vs. baseline, paired t-test).</p

    Diagram showing the location and different layers of the EC.

    No full text
    <p>Dotted line shows the location of cutting. Recordings were conducted form layer III pyramidal neurons with a stimulation electrode placed in ∼200 µm from the recorded neuron in layer III. DG, dentate gyrus; Subc, subiculum; PER, perirhinal; EC, entorhinal cortex.</p

    Roles of AC-cAMP-PKA pathway in adenosine-induced depression of glutamate release.

    No full text
    <p>A<sub>1</sub>–A<sub>2</sub>, Application of adenosine did not inhibit AMPA EPSCs in slices pretreated with PTX but still induced robust inhibition of AMPA EPSCs in slices undergone the same fashion of treatment without PTX. <b>A<sub>1</sub>,</b> AMPA EPSC amplitudes recorded every 3 s before, during and after the application of adenosine. Slices were pretreated with PTX in the extracellular solution bubbled with 95% O<sub>2</sub> and 5% CO<sub>2</sub> for ∼10 h (<i>empty circles</i>). For control (<i>solid circles</i>), slices underwent the similar treatment without PTX. Upper panel shows the average of 10 EPSCs at different time points in the figure. <b>A<sub>2</sub>,</b> Averaged data. <b>B<sub>1</sub>–B<sub>2</sub>,</b> Bath application of MDL-12,330A (50 µM) alone significantly reduced AMPA EPSCs and reduced adenosine-induced depression of AMPA EPSCs. <b>B<sub>1</sub>,</b> Raw data from one cell. <b>B<sub>2</sub>,</b> Averaged data from 5 cells. <b>C<sub>1</sub>–C<sub>2</sub>,</b> Bath application of KT5720 (1 µM) alone significantly reduced AMPA EPSCs and reduced adenosine-induced depression of AMPA EPSCs. <b>C<sub>1</sub>,</b> Raw data from one cell. <b>C<sub>2</sub>,</b> Data averaged from 5 cells.</p

    Adenosine decreases the amplitude of evoked AMPA EPSCs via activation of A<sub>1</sub> ARs without altering that of the evoked IPSCs recorded from layer III pyramidal neurons in the medial EC.

    No full text
    <p>A, Bath application of adenosine (100 µM) reversibly inhibited the evoked AMPA EPSCs (n = 15, p<0.001 vs. baseline, paired t-test). Upper panel shows the average of 10 EPSCs recorded at different time points in the figure. Stimulation artifacts were blanked for clarity (same for the rest of the figures). <b>B,</b> Bath application of the A<sub>1</sub> AR antagonist, DPCPX (1 µM) completely blocked adenosine-induced depression of AMPA EPSCs (n = 5, p = 0.8 vs. baseline, paired t-test). <b>C,</b> Bath application of the A<sub>1</sub> AR agonist, NCPA (2 µM), inhibited AMPA EPSCs (n = 10, p<0.001 vs. baseline, paired t-test). <b>D,</b> Application of the antagonists for receptors other than A<sub>1</sub> ARs failed to block adenosine-induced depression of AMPA EPSCs (One-way ANOVA followed by Dunnett test, *** p<0.001 vs. adenosine alone). <b>E,</b> Concentration-response curve of adenosine. The numbers in the parentheses are the numbers of cells used for each concentration. <b>F,</b> Bath application of dipyridamole (1 µM), an adenosine transporter inhibitor, significantly reduced the evoked EPSCs (n = 10, p<0.001, paired t-test) suggesting that endogenously released adenosine decreases AMPA EPSCs. <b>G,</b> Prior application of DPCPX, an A<sub>1</sub> AR blocker, blocked dipyridamole-induced depression of AMPA EPSCs (n = 5, p = 0.85 vs. baseline, paired t-test) suggesting that the inhibitory effect of dipyridamole is mediated via activation of A<sub>1</sub> ARs. <b>H,</b> Bath application of adenosine (100 µM) had no effects on the evoked IPSCs recorded at −70 mV from layer III pyramidal neurons (n = 7, p = 0.84 vs. baseline, paired t-test). The extracellular solution contained DNQX (20 µM) and <i>dl</i>-APV (100 µM). At the end of the experiments, application of bicuculline (20 µM) completely blocked IPSCs indicating that the recorded IPSCs were mediated by activation of GABA<sub>A</sub> receptors.</p

    Adenosine decreases mEPSC frequency with no effects on mEPSC amplitudes.

    No full text
    <p>A, mEPSCs recorded from a layer III pyramidal neuron in the presence of TTX (1 µM) before, during and after application of adenosine (100 µM). <b>B,</b> Time course of the mEPSC frequency averaged from 11 cells. Numbers of mEPSCs at each min were normalized to that of mEPSCs in the 5 min prior to the application of adenosine (n = 11, p<0.001 vs. baseline, paired t-test). <b>C,</b> Cumulative frequency distribution from a layer III pyramidal neuron before (<i>solid</i>) and during (<i>dotted</i>) the application of adenosine. Note that adenosine increased the intervals of the mEPSC (decreased mEPSC frequency, p<0.001, Kolmogorov-Smirnov test). <b>D,</b> Cumulative amplitude distribution from the same cell before (<i>solid</i>) and during (<i>dotted</i>) the application of adenosine (p = 0.08, Kolmogorov-Smirnov test). <b>E,</b> Summarized data for adenosine-induced reduction of mEPSC frequency (n = 11, paired t-test). <b>F,</b> Adenosine failed to alter significantly mEPSC amplitudes (n = 11, paired t-test).</p
    corecore